Myriad Genetics, Inc. logo MYGN - Myriad Genetics, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 8
HOLD 22
SELL 6
STRONG
SELL 0
| PRICE TARGET: $3.00 DETAILS
HIGH: $3.00
LOW: $3.00
MEDIAN: $3.00
CONSENSUS: $3.00
DOWNSIDE: 5.66%

Stock News

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad's website at investor.myriad.com.

Aug 27, 2026 05:05 AM • globenewswire.com
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2026, Myriad Genetics reported that its second-quarter revenue declined 11% year-.

Aug 13, 2026 04:00 PM • businesswire.com (Hide legal announcements)
Reviewing Dyadic International (NASDAQ:DYAI) and Myriad Genetics (NASDAQ:MYGN)

Reviewing Dyadic International (NASDAQ:DYAI) and Myriad Genetics (NASDAQ:MYGN)

Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership. Earnings and Valuation This table compares Dyadic

Aug 11, 2026 12:18 AM • defenseworld.net
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)

Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses. Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses.

Aug 06, 2026 06:09 AM • globenewswire.com (Hide legal announcements)
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

Aug 05, 2026 04:00 PM • globenewswire.com (Hide legal announcements)
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA of $37 million to $49 million and adjusted gross margin of 68% to 69% for full-year 2026. Roughly three months later, the adjusted EBITDA range was suspended outright and MYGN shares dropped. If you held Myriad Genetics stock and lost money, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (2.

Aug 05, 2026 06:07 AM • businesswire.com (Hide legal announcements)
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.

Aug 04, 2026 07:27 AM • globenewswire.com (Hide legal announcements)
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cycle initiatives expected to improve reimbursement predictability and performance.

Jul 30, 2026 12:05 PM • globenewswire.com

Price Targets